Jason Haas, Chief Financial Officer at Odyssey Therapeutics, Inc. (ODTX), bought 1,000 shares at $20.00 ($20K) on 2026-05-08, disclosed to the SEC on 2026-05-11.
CFO Jason Haas purchased 1,000 shares at $20.00, marking the largest insider purchase in the company's history. This significant buyback by C-suite leadership suggests confidence in the stock's valuation following its recent IPO debut.
The stock is currently trading 14.62% below its 52-week high of $20.18, which aligns closely with the insider's purchase price of $20.00.
The stock slipped lower following its IPO debut on May 11, 2026, as reported in recent news.
Something here stands out, but not much.
| Filing → |
| SYRS | SELL | 2024-11-20 | $29K | — | Filing → |
| SYRS | BUY | 2024-09-12 | $292K | — | Filing → |